
















PHYSICAL THERAPY

- | | | | |
|--|---|---|---|
|  Combination therapy |  Laser therapy |  Traction therapy |  MAGCELL® |
|  Electrotherapy |  Shockwave therapy |  Cryotherapy |  vocaSTIM® |
|  Ultrasound therapy |  Shortwave therapy |  Magnetotherapy | |
|  Vacuum application |  Microwave therapy |  DEEP OSCILLATION® | |





MAGCELL® ARTHRO

Pain-alleviating and movement-promoting effect for osteoarthritis


MAGCELL® ARTHRO significantly improves general symptoms (WOMAC total score) and individual scores for pain, stiffness and daily activity in osteoarthritis (ARC criteria II and III). The therapy can be applied several times daily as a complementary treatment without side effects and may thus help to reduce intake of pain medication.



Special features, technical data and standard accessories are identical to MAGCELL® MICROCIRC


WOMAC TOTAL SCORE

Source: Wuschech et al. (2015)



WOMAC PAIN SCORE

Source: Wuschech et al. (2015)



In a randomised controlled study on the effect of MAGCELL® ARTHRO for knee arthritis with osteoarthritis level 2.8 ± 0.8 (American College of Rheumatology criteria) at the primary clinical end point (WOMAC total score) median increase of 0.7 P (non-significant) was recorded in the placebo group between T0 and T1 (18 days), yet in the MAGCELL®-group a significant local decrease of 21.8 P. During the study no undesirable incidents or side effects occurred related to therapy.

The WOMAC individual scores for pain, stiffness and daily activity also resulted in significant local improvements in the MAGCELL®-group compared to a slight median increase (non-significant) in the placebo group. A highly significant result ($p < 0.001$) in favour of the MAGCELL®-group was recorded for the individual parameter pain reduction compared to the placebo in the difference between the beginning and end of treatment.


MAGCELL® MICROCIRC

Blood flow stimulation and reduction of sensory neurotoxicities in cytostatic-induced polyneuropathy


MAGCELL® MICROCIRC can positively influence symptoms of neurotoxicities like sensory ataxia, neuropathy and neuropathic pain symptoms (especially CIPN I-IV) on hands and feet as a result of chemotherapy. Moreover a significant increase in nerve conductivity speed (ulnar nerve) was achieved by the treatment.

BLOOD FLOW STIMULATION

Source: Funk et al. (2014)



1. Control (without MAGCELL® MICROCIRC)



2. Two minutes after treatment with MAGCELL® MICROCIRC

MAGCELL® MICROCIRC significantly increases micro-circulation ($p < 0,001$) while nitric oxide (NO) has a blood vessel dilatory effect. The authors recommend the therapy for clinical situations where an improvement in micro circulation is identified, like for instance in the case of chronic tissue repair.

TECHNICAL DATA

Protection class	Internal power supply
Power supply	2 x 1.5 V R6 alkaline batteries
Magnetic field strength max.	200 mT
Treatment duration	MAGCELL® ARTHRO 2.5 min.
Treatment duration	MAGCELL® MICROCIRC 5 min.
Dimensions (W x H x D)	83 x 152 x 25 mm
Weight	0.21 kg

STANDARD ACCESSORIES

[2]	Batteries
[1]	Metal case
[1]	Operating instructions



SPECIAL FEATURES

ELECTRODE-FREE ELECTROTHERAPY

Electrode-free electrotherapy for therapists and patients

Pulsating electromagnetic fields (PEMF)

Field strength more than 1000 gauss

Effective treatment concept due to repeatable short-treatment periods

Through-textile treatment (even through shoes)

GENERAL FEATURES

Very easy one-button operation

Battery-driven

Optical and acoustic function control

Automatic switch-off at the end of the therapy period

ADDRESS

PHYSIOMED ELEKTROMEDIZIN AG
Hutweide 10
91220 Schnaittach
Germany

PHONE

+49(0)9126/2587-0

FAX

+49(0)9126/2587-25

E-MAIL

info@physiomed.de

WEB

www.physiomed.de

DEALER MARK / STAMP

GB 03/2017. Errors excepted. Technical data subject to change without notice.

TECHNOLOGY FOR THERAPY

PHYSIOMED[®]